{'fraction_non_alphanumeric': 0.02650602409638554, 'fraction_numerical': 0.0, 'mean_word_length': 4.9784172661870505, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Constant Drug Dose Leading Long-Term Non-Progressor for HIV-Infected Patients with RTI and PI

This paper proposes a therapy that uses a constant dosage of Reverse Transcription Inhibitor (RTI) and Protease Inhibitor (PI) to help an HIV-infected patient achieve Long-Term Non-Progressor (LTNP) status. Based on the analysis of the Cytotoxic T Lymphocyte precursor (CTLp) concentration at the equilibrium point and the bifurcation of the equilibrium points, we found that therapy with a drug whose efficacy was below a certain level produced a higher CTLp concentration at the equilibrium point. We found that it is possible for a less-than-full constant dosage treatment to induce LTNP status. In fact, the treatment with an efficacy less than that of a full treatment proved to be more efficient when considering controllability.